The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Thoratec's revenues will grow 8.9% and EPS will drop 0.0%.
The average estimate for revenue is $119.1 million. On the bottom line, the average EPS estimate is $0.38.
Last quarter, Thoratec chalked up revenue of $117.8 million. GAAP reported sales were 15% higher than the prior-year quarter's $102.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.49. GAAP EPS of $0.41 for Q3 were 37% higher than the prior-year quarter's $0.30 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 69.3%, 140 basis points better than the prior-year quarter. Operating margin was 27.8%, 80 basis points better than the prior-year quarter. Net margin was 20.6%, 310 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $482.0 million. The average EPS estimate is $1.83.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 153 members out of 174 rating the stock outperform, and 21 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 42 give Thoratec a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thoratec is outperform, with an average price target of $40.00.
Is Thoratec the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Thoratec to My Watchlist.